Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Riegersperger, Markus ^a   Herkner, Harald ^a   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ADPKD; Autosomal dominant polycystic kidney disease; Mammalian target of rapamycin; mTOR; mTOR inhibition; PKD; Pulsed; Rapamycin; Sirolimus

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; LIPID; PHOSPHATE; PLACEBO; POTASSIUM; PROTEIN; RAPAMYCIN; SODIUM; UREA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; ARTHRALGIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIARRHEA; DRUG INDUCED HEADACHE; DRUG PULSE THERAPY; DRUG SAFETY; FEVER; FOOT AND MOUTH DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MEDICATION COMPLIANCE; NAUSEA; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHOSPHATE BLOOD LEVEL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; UREA BLOOD LEVEL; URINARY TRACT INFECTION; WOUND HEALING IMPAIRMENT; ANTAGONISTS AND INHIBITORS; AUSTRIA; BLOOD; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HEMODIALYSIS; KIDNEY; MALE; METABOLISM; METHODOLOGY; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AUSTRIA; BIOMARKERS; CLINICAL PROTOCOLS; CREATININE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PULSE THERAPY, DRUG; RENAL DIALYSIS; RESEARCH DESIGN; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84928884008     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0692-3     Document Type: Article

References (21)

1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149-68.
2. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-12.
3. Chapman AB. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol. 2007;18(5):1399-407.
4. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41(5):1311-9.
5. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005;16(1):46-51.
6. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21(3):598-604.
7. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820-9.
8. Walz G, Budde K, Mannaa MD, Nürnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830-40.
9. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation. 2006;82(1):17-22.
10. Boni JP, Hug B, Leister C, Sonnichsen D. Temsirolimus, a novel mTOR inhibitor: its clinical development for renal cell carcinoma and other tumors. Semin Oncol. 2009;36(6):18-25.
11. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
12. Moe SM, Drüeke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease - mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
15. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, et al. The effect of angiotensin-converting enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67(1):265-71.
16. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-60.
17. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609-19.
18. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int. 2009;75(2):235-41.
19. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 2008;73(1):108-16.
20. Grantham JJ, Mulamalla S, Grantham CJ, Wallace DP, Cook LT, Wetzel LH, et al. Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin J Am Soc Nephrol. 2012;7(7):1087-93.
21. Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol. 2014;9(5):881-8.